Arena's Belviq scripts spike on DTC, stepped-up field force; Sanofi inks cancer marketing pact with India's Emcure;

> Arena Pharmaceuticals ($ARNA) reported a 43% rise in second-quarter sales of its obesity drug Belviq as DTC ads and a beefed-up sales force gained momentum. Report

> Sanofi ($SNY) tapped India's Emcure Pharmaceuticals to market its oncology drugs Taxotere, Jevtana, Fludara and Fasturtec in that country. Report

> It's official: Roche ($RHHBY) has won approval to market Avastin in Europe as a treatment for recurrent ovarian cancer resistant to platinum-based chemo. Release | Report

> Pfizer's ($PFE) Enbrel scored a European nod to treat a rare inflammatory joint disorder at early stages of the disease. Report

> Ashfield Healthcare recruited Wendy Wolf away from Publicis Touchpoint Solutions to be its SVP of commercial and clinical operations. Report

And Finally... A new scientific review found that aspirin could stave off bowel and stomach cancers. Report

Suggested Articles

Roche’s Tecentriq didn't repeat its prior TNBC success when tested in tandem with chemo med paclitaxel in previously untreated metastatic patients.

Alexion Pharmaceuticals names its first chief diversity officer as the rare disease specialist looks to cultivate diversity and inclusion.

Back in 2015, GlaxoSmithKline traded away its marketed cancer assets and began rebuilding its oncology pipeline. Those efforts have finally paid off.